CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial performance with a 15% revenue increase and improved gross margins. Strategic initiatives and revenue guidance are optimistic, with a raised full-year guidance and market expansion plans. Although there are no shareholder return plans mentioned, the positive financial metrics and growth strategies outweigh potential risks, leading to an overall positive sentiment.
Key Financial Performance
Revenue Revenue for Q4 2025 was $45 million, representing a 15% increase year-over-year. The growth was driven by strong demand for our flagship product and expansion into new markets.
Gross Margin Gross margin improved to 68% in Q4 2025, up from 65% in Q4 2024. This improvement was attributed to operational efficiencies and cost reductions in manufacturing.
Operating Expenses Operating expenses were $25 million in Q4 2025, a 10% increase compared to Q4 2024. The increase was primarily due to higher R&D investments and marketing expenses to support new product launches.
Net Income Net income for Q4 2025 was $5 million, compared to $3 million in Q4 2024, marking a 67% increase. This was driven by higher revenue and improved gross margins.
Cash Flow Operating cash flow was $10 million in Q4 2025, up from $7 million in Q4 2024, reflecting stronger collections and improved profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management highlighted that forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied. This indicates potential challenges in meeting future expectations or predictions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: CeriBell is focusing on expanding its product line to include more advanced neurodiagnostic tools. The company is also planning to enter new international markets to increase its global footprint. Additionally, CeriBell is investing in research and development to enhance its existing products and develop new technologies that can provide more accurate and faster diagnostics.
Revenue Expectations: CeriBell expects a revenue growth of 15% to 20% in the next fiscal year, driven by increased demand for its neurodiagnostic products and expansion into new markets.
Margin Projections: The company anticipates maintaining a stable gross margin of approximately 60% as it scales its operations and optimizes its supply chain.
Capital Expenditures: CeriBell plans to increase its capital expenditures by 10% to support the expansion of its manufacturing facilities and the development of new technologies.
Market Trends: The company expects the neurodiagnostic market to grow significantly over the next few years, driven by technological advancements and increasing awareness of neurological disorders.
Business Segment Performance: CeriBell's neurodiagnostic segment is expected to see the highest growth, with projections of a 25% increase in sales due to new product launches and market expansion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made in the transcript.
Share Buyback Program: No specific mention of a share buyback program was made in the transcript.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Associates Inc
Blair LLC
Blumberg Chief
Celine Lozada
Cohen Ladenburg
Cui Raymond
Director Scott
Division Brandon
Division Elaine
Division Lilia
Division Marie
Division PM
EST Hello
Elaine Cui
Hello Ceribell
Inc Research
Instructions Investor
LLC Research
LLC Travis
Ladenburg Thalmann
Lilia Celine
Lozada JPMorgan
Marie Thibault
Officer Gilmartin
PM EST
Raymond Associates
Relations statement
Research Division
Scott Blumberg
Thalmann Co
Thibault BTIG
Travis Steed
CBLL Transcript
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary shows strong financial performance with a 15% revenue increase and improved gross margins. Strategic initiatives and revenue guidance are optimistic, with a raised full-year guidance and market expansion plans. Although there are no shareholder return plans mentioned, the positive financial metrics and growth strategies outweigh potential risks, leading to an overall positive sentiment.
Caris Life Sciences, Inc. (CAI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
CeriBell, Inc. (CBLL) Q3 2025 Earnings Call Transcript
Positive11-4
Ceribell's earnings call presents a positive outlook with raised revenue guidance, strong gross margins, and strategic supply chain adjustments. Their market expansion into pediatrics and neonates, coupled with a new 510(k) clearance, enhances growth prospects. While competition and IP litigation pose risks, they haven't significantly impacted performance. The Q&A section reveals optimism about account growth and strategic partnerships, with some concerns about resource limitations and competition. Overall, the company's strategic initiatives and optimistic guidance suggest a positive stock price movement over the next two weeks.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
